Artiva Biotherapeutics (ARTV) Equity Ratio (2023 - 2025)
Artiva Biotherapeutics (ARTV) has disclosed Equity Ratio for 3 consecutive years, with 0.84 as the latest value for Q4 2025.
- On a quarterly basis, Equity Ratio fell 5.69% to 0.84 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.84, a 5.69% decrease, with the full-year FY2025 number at 0.84, down 5.69% from a year prior.
- Equity Ratio was 0.84 for Q4 2025 at Artiva Biotherapeutics, down from 0.87 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.89 in Q3 2024 to a low of 2.52 in Q2 2024.
- A 3-year average of 0.15 and a median of 0.87 in 2025 define the central range for Equity Ratio.
- Peak YoY movement for Equity Ratio: skyrocketed 157.78% in 2024, then decreased 5.69% in 2025.
- Artiva Biotherapeutics' Equity Ratio stood at 1.54 in 2023, then skyrocketed by 157.78% to 0.89 in 2024, then fell by 5.69% to 0.84 in 2025.
- Per Business Quant, the three most recent readings for ARTV's Equity Ratio are 0.84 (Q4 2025), 0.87 (Q3 2025), and 0.88 (Q2 2025).